Korean J Hematol 1994; 29(1):
Published online March 31, 1994
© The Korean Society of Hematology
박미정, 오승환, 유철주, 양창현, 김길영
연세대학교 의과대학 소아과학교실
Background: Although the clinical course of acute lymphoblastic leukemia has been reported in many literatures, there has not been any report on the subject of clinical outcome of relapsed cases in Korea. The purpose of this study is to evaluate clinical outcome in relapsed acute lymphoblastic leukemia.
Methods: We evaluated 122 patients with acute lymphoblastic leukemia diagnosed at Yonsei University College of Medicine from January, 1987 to December, 1991.
Results: 1) Among 122 patients 54 cases(44.3%) relapsed.
2) At initial diagnosis, in cases of L2 or L3(FAB classification) and leukocyte count greater than 100×109/L, relapse was
significantly increased. No statistical significant difference was found in sex and age.
3) The mean time duration from remission induction to relapse was as follows ; Bone marrow relapse in 27 cases(22.1%) with time interval of 14 months, CNS relapse in 14
cases(11.5%) with time interval of 11 months, testis relapse in 7 cases(5.7%) with time interval of 28 months.
4) In 36 cases which relapsed only once, their mean survival time was 9.5 months, in 13 cases of relapsed twice, their mean survival time was 5.1 months, in 5 cases of relapsed thrice, their mean survival time was 4.4 months.
5) In cases of continuous complete remission, 3-year survival rate was 86%, those which relapse once was 42% and those which relapse twice was 18%.
Conclusions : The prognosis of relapsed acute lymphoblastic leukemia is still found to be poor and further research for intensified combination chemotherapy according to risk
group is needed.
Keywords Relapse; Acute lymphoblastic leukemia; Childhood;
Korean J Hematol 1994; 29(1): 23-30
Published online March 31, 1994
Copyright © The Korean Society of Hematology.
박미정, 오승환, 유철주, 양창현, 김길영
연세대학교 의과대학 소아과학교실
Mi Jung Park, Seung Hwan Oh, Chuhl Joo Lyu, Chang Hyun Yang, Kil Young Kim
Department of Pediatrics, Yonsei University College of Medicine, Seoul, Korea
Background: Although the clinical course of acute lymphoblastic leukemia has been reported in many literatures, there has not been any report on the subject of clinical outcome of relapsed cases in Korea. The purpose of this study is to evaluate clinical outcome in relapsed acute lymphoblastic leukemia.
Methods: We evaluated 122 patients with acute lymphoblastic leukemia diagnosed at Yonsei University College of Medicine from January, 1987 to December, 1991.
Results: 1) Among 122 patients 54 cases(44.3%) relapsed.
2) At initial diagnosis, in cases of L2 or L3(FAB classification) and leukocyte count greater than 100×109/L, relapse was
significantly increased. No statistical significant difference was found in sex and age.
3) The mean time duration from remission induction to relapse was as follows ; Bone marrow relapse in 27 cases(22.1%) with time interval of 14 months, CNS relapse in 14
cases(11.5%) with time interval of 11 months, testis relapse in 7 cases(5.7%) with time interval of 28 months.
4) In 36 cases which relapsed only once, their mean survival time was 9.5 months, in 13 cases of relapsed twice, their mean survival time was 5.1 months, in 5 cases of relapsed thrice, their mean survival time was 4.4 months.
5) In cases of continuous complete remission, 3-year survival rate was 86%, those which relapse once was 42% and those which relapse twice was 18%.
Conclusions : The prognosis of relapsed acute lymphoblastic leukemia is still found to be poor and further research for intensified combination chemotherapy according to risk
group is needed.
Keywords: Relapse, Acute lymphoblastic leukemia, Childhood,